Skip to main content
Erschienen in: World Journal of Urology 6/2012

01.12.2012 | Original Article

Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer

verfasst von: Eugene K. Cha, Lenuta-Ancuta Tirsar, Christian Schwentner, Joerg Hennenlotter, Paul J. Christos, Arnulf Stenzl, Christine Mian, Thomas Martini, Armin Pycha, Shahrokh F. Shariat, Bernd J. Schmitz-Dräger

Erschienen in: World Journal of Urology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bladder cancer is frequently diagnosed during a workup for hematuria. However, most patients with microscopic hematuria and many with gross hematuria are not appropriately referred to urologists. We hypothesized that in patients presenting with asymptomatic hematuria the risk of having bladder cancer can be predicted with high accuracy. Toward this end, we analyzed risk factors in patients with asymptomatic hematuria and developed a nomogram for the prediction of bladder cancer presence.

Methods

Data from 1,182 consecutive subjects without a history of bladder cancer undergoing initial evaluation for asymptomatic hematuria were collected at three centers. Clinical risk factors including age, gender, smoking status, and degree of hematuria were recorded. All subjects underwent standard workup including voided cytology, upper tract imaging, and cystourethroscopy. Factors associated with the presence of bladder cancer were evaluated by univariable and multivariable logistic regression analyses. The multivariable analysis was used to construct a nomogram. Internal validation was performed using 200 bootstrap samples.

Results

Of the 1,182 subjects who presented with asymptomatic hematuria, 245 (20.7 %) had bladder cancer. Increasing age (OR = 1.03, p < 0.0001), smoking history (OR = 3.72, p < 0.0001), gross hematuria (OR = 1.71, p = 0.002), and positive cytology (OR = 14.71, p < 0.0001) were independent predictors of bladder cancer presence. The multivariable model achieved 83.1 % accuracy for predicting the presence of bladder cancer.

Conclusions

Bladder cancer presence can be predicted with high accuracy in patients who present with asymptomatic hematuria. We developed a nomogram to help optimize referral patterns (i.e., timing and prioritization) of patients with asymptomatic hematuria.
Literatur
1.
2.
Zurück zum Zitat Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34PubMedCrossRef Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34PubMedCrossRef
3.
Zurück zum Zitat Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M et al (2007) Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 25:285–295PubMedCrossRef Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M et al (2007) Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 25:285–295PubMedCrossRef
4.
Zurück zum Zitat Silverman DT, Levin LI, Hoover RN, Hartge P (1989) Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 81:1472–1480PubMedCrossRef Silverman DT, Levin LI, Hoover RN, Hartge P (1989) Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 81:1472–1480PubMedCrossRef
6.
Zurück zum Zitat Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL et al (2001) Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy–part I: definition, detection, prevalence, and etiology. Urology 57:599–603PubMedCrossRef Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL et al (2001) Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy–part I: definition, detection, prevalence, and etiology. Urology 57:599–603PubMedCrossRef
7.
Zurück zum Zitat Davis R, Jones SJ, Barocas DA, Castle EP, Lang EK, et al. (2012) diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. American Urological Association Guidelines May 2012 Davis R, Jones SJ, Barocas DA, Castle EP, Lang EK, et al. (2012) diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. American Urological Association Guidelines May 2012
8.
Zurück zum Zitat Cohen RA, Brown RS (2003) Clinical practice Microscopic hematuria. N Engl J Med 348:2330–2338PubMedCrossRef Cohen RA, Brown RS (2003) Clinical practice Microscopic hematuria. N Engl J Med 348:2330–2338PubMedCrossRef
9.
Zurück zum Zitat Nieder AM, Lotan Y, Nuss GR, Langston JP, Vyas S et al (2010) Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol 28:500–503PubMedCrossRef Nieder AM, Lotan Y, Nuss GR, Langston JP, Vyas S et al (2010) Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol 28:500–503PubMedCrossRef
10.
Zurück zum Zitat Johnson EK, Daignault S, Zhang Y, Lee CT (2008) Patterns of hematuria referral to urologists: does a gender disparity exist? Urology 72:498–502 Discussion 498–502PubMedCrossRef Johnson EK, Daignault S, Zhang Y, Lee CT (2008) Patterns of hematuria referral to urologists: does a gender disparity exist? Urology 72:498–502 Discussion 498–502PubMedCrossRef
11.
Zurück zum Zitat Summerton N, Mann S, Rigby AS, Ashley J, Palmer S et al (2002) Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract 52:284–289PubMed Summerton N, Mann S, Rigby AS, Ashley J, Palmer S et al (2002) Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract 52:284–289PubMed
12.
Zurück zum Zitat Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI (2009) Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103:1368–1374PubMedCrossRef Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI (2009) Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 103:1368–1374PubMedCrossRef
13.
Zurück zum Zitat Efron B, Tibshirani R (1993) An introduction to the bootstrap., XviChapman & Hall, New York, p 436 Efron B, Tibshirani R (1993) An introduction to the bootstrap., XviChapman & Hall, New York, p 436
14.
Zurück zum Zitat Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y et al (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774–781PubMedCrossRef Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y et al (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774–781PubMedCrossRef
15.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef
16.
Zurück zum Zitat Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448PubMedCrossRef Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448PubMedCrossRef
17.
Zurück zum Zitat Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ et al (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28:389–400PubMedCrossRef Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ et al (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28:389–400PubMedCrossRef
18.
Zurück zum Zitat Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF (2008) Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol 60:247–253PubMed Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF (2008) Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol 60:247–253PubMed
19.
Zurück zum Zitat Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS (2009) Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer 115:988–996PubMedCrossRef Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS (2009) Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer 115:988–996PubMedCrossRef
20.
Zurück zum Zitat Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S (2002) Delay and survival in bladder cancer. BJU Int 89:868–878PubMedCrossRef Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S (2002) Delay and survival in bladder cancer. BJU Int 89:868–878PubMedCrossRef
21.
Zurück zum Zitat Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA et al (2010) Delays in diagnosis and bladder cancer mortality. Cancer 116(22):5235–5242PubMedCrossRef Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA et al (2010) Delays in diagnosis and bladder cancer mortality. Cancer 116(22):5235–5242PubMedCrossRef
22.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Suardi N, Kattan MW (2008) Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14:4400–4407PubMedCrossRef Shariat SF, Karakiewicz PI, Suardi N, Kattan MW (2008) Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14:4400–4407PubMedCrossRef
23.
Zurück zum Zitat Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113:3075–3099PubMedCrossRef Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113:3075–3099PubMedCrossRef
24.
Zurück zum Zitat Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW et al (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60:1423–1427PubMedCrossRef Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW et al (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60:1423–1427PubMedCrossRef
25.
Zurück zum Zitat Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S et al (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105:300–308PubMedCrossRef Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S et al (2010) The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 105:300–308PubMedCrossRef
26.
Zurück zum Zitat Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H et al (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97:997–1001PubMedCrossRef Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H et al (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97:997–1001PubMedCrossRef
27.
Zurück zum Zitat Buntinx F, Wauters H (1997) The diagnostic value of macroscopic haematuria in diagnosing urological cancers: a meta-analysis. Fam Pract 14:63–68PubMedCrossRef Buntinx F, Wauters H (1997) The diagnostic value of macroscopic haematuria in diagnosing urological cancers: a meta-analysis. Fam Pract 14:63–68PubMedCrossRef
28.
Zurück zum Zitat Messing EM, Madeb R, Young T, Gilchrist KW, Bram L et al (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107:2173–2179PubMedCrossRef Messing EM, Madeb R, Young T, Gilchrist KW, Bram L et al (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107:2173–2179PubMedCrossRef
29.
Zurück zum Zitat Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I et al (2002) Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol 20:82–88PubMedCrossRef Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I et al (2002) Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol 20:82–88PubMedCrossRef
30.
Zurück zum Zitat Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD et al (2007) Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100:1254–1258PubMedCrossRef Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD et al (2007) Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100:1254–1258PubMedCrossRef
Metadaten
Titel
Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer
verfasst von
Eugene K. Cha
Lenuta-Ancuta Tirsar
Christian Schwentner
Joerg Hennenlotter
Paul J. Christos
Arnulf Stenzl
Christine Mian
Thomas Martini
Armin Pycha
Shahrokh F. Shariat
Bernd J. Schmitz-Dräger
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 6/2012
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-012-0979-x

Weitere Artikel der Ausgabe 6/2012

World Journal of Urology 6/2012 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.